Trial Profile
Effect of alemtuzumab in German patients with Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TREAT-MS
- 26 Apr 2022 Interim Results (cut-off 02 FEB 2021, n=494 ) presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 15 Oct 2021 Interim results (as of Feb 2021; n=907) presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 01 May 2020 Interim results (as of October 2018; n=778) of sub-group analysis by timing of initiation assessing efficacy of alemtuzumab in RRMS patients, presented at the 72nd Annual Meeting of the American Academy of Neurology.